What is Hibercell?
Hibercell is dedicated to pioneering therapies that target adaptive-stress driven vulnerabilities within cancer cells. Their approach aims to overcome the persistent challenges of treatment resistance, cancer relapse, and metastasis. The company's pipeline includes clinical-stage therapeutic candidates such as HC-7366, HC-5404, and Odetiglucan, all designed to exploit stress-induced vulnerabilities to improve patient outcomes. Led by a seasoned team of biotech executives, Hibercell integrates traditional drug development methodologies with advanced computational expertise to create next-generation cancer treatments.
How much funding has Hibercell raised?
Hibercell has raised a total of $158.2M across 3 funding rounds:
Series A
$60.8M
Series B
$67.4M
Debt
$30M
Series A (2019): $60.8M with participation from ARCH Venture Partners, 6 Dimensions Capital, Celgene Corporation, and Hillhouse Capital
Series B (2021): $67.4M led by Trinitas Capital Management, Huizenga Capital Management, Bristol-Myers Squibb, Monashee Investment Management, Hercules Capital, Magnetic Ventures, Mount Sinai Health System, Tekla Healthcare Opportunities, and ARCH VENTURE PARTNERS
Debt (2021): $30M supported by Hercules Capital
Key Investors in Hibercell
Trinitas Capital Management
Trinitas Capital Management is a credit-focused investment firm specializing in senior secured bank loans and structured credit products, likely seeking to enhance returns through collateralized loan obligations and separate accounts.
Huizenga Capital Management
Huizenga Capital Management adopts a global investment approach, directly investing in private opportunities such as operating companies and real estate, alongside engaging with external money managers.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and manufacturing prescription medications for serious unmet medical needs in oncology, cardiovascular disease, immunoscience, and virology.
What's next for Hibercell?
With substantial enterprise-level backing and a recent strategic investment, Hibercell is well-positioned to advance its clinical-stage therapeutic candidates. The company's focus on exploiting cancer cell vulnerabilities offers a promising avenue for developing treatments against resistant and relapsed cancers. Continued investment and strategic partnerships will likely fuel further research and development, potentially leading to new paradigms in cancer therapy and improved patient prognoses. The company's commitment to combining drug development with computational science suggests a forward-thinking strategy aimed at accelerating therapeutic breakthroughs.
See full Hibercell company page
